Shots: The first patient has been dosed in a P-II/III clinical trial of HLX10 in combination with HLX04 (bevacizumab) and CT for 1L treatment of mCRC The combination regimen aims […]readmore
Tags : HLX04
Shots: The P-III HLX04-mCRC03 study involves assessing the efficacy, safety and immunogenicity of HLX04 vs reference bevacizumab (7.5 mg/kg, q3w or 5 mg/kg, q2w) + CT (Xelox or mFOLFOX6) as […]readmore
Shots: The P-III HLX04-mCRC03 study involve assessing of HLX04 (7.5mg/kg, q3w, when combined with XELOX or 5mg/kg, q2w when combined with mFOLFOX6) vs reference bevacizumab + CT (XELOX or mFOLFOX6) […]readmore
Shots: NMPA has accepted the NDA of HLX04, based on the series of study data, including comparative pharmaceutical quality studies, comparative non-clinical studies & clinical studies. The NDA acceptance makes […]readmore
Biosimilars
Clinical Trials
Regulatory
Henlius Reports Positive Results of HLX04 (biosimilar, bevacizumab) in P-III
Shots: HLX04 is a biosimilar that binds to vascular endothelial growth factor (VEGF) for inhibiting angiogenesis where VEGF acts for promoting growth of blood vessels can inhibit tumor angiogenesis further […]readmore